Abstract The pioneering discovery by Yamanaka and colleagues enabling the reprogramming of terminally differentiated somatic cells into induced pluripotent stem cells (iPSCs) has opened transformative opportunities for disease modeling and regenerative medicine, particularly in the context of inherited monogenic disorders.
Peter Loskill
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Peter
Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack